Table 1 Descriptive analysis of all antiretroviral therapy cohort participants (n = 1350)

Female

808 (59.8%)

Median age in years (IQR)

35.5 (30.2, 41.9)

CD4 count at baseline

n = 1257

Median number of cells per μL (IQR)

83 (27,147)

Count <50 cells per μL

473 (37.6%)

Viral load at baseline

n = 1187

Median log10 copies per mL (IQR)

4.92 (4.42, 5.38)

Count >5 log10 copies per mL

533 (44.9%)

Haemoglobin at baseline

n = 1206

Median g/mL (IQR)

11.5 (9.9, 13)

Count <8 g/mL (severely anaemic)

105 (8.7%)

Body mass index (BMI) at baseline

n = 854

Median kg/m² (IQR)

21.4 (18.5, 24.3)

Count <18.5 kg/m² (underweight)

207 (24.2%)

Previous tuberculosis diagnosis

314 (23.3%)

Current smoker

177 (13.1%)

Currently drinks alcohol

149 (11%)

Previous tuberculosis preventive therapy

30 (2.2%)

Treatment combination

Stavudine/lamivudine/nevirapine

562 (41.6%)

Stavudine/lamivudine/efavirenz

672 (49.8%)

Zidovudine/lamivudine/efavirenz

55 (4.1%)

Other

61 (4.5%)